Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer
NCT ID: NCT04636788
Last Updated: 2020-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
102 participants
INTERVENTIONAL
2020-11-01
2022-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably.
By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pancreatic cancer group
pancreatic cancer, anticipated participants: 68
other pancreatic lesions including MCN, SCN, IPMN, SPN without malignant pathological finding chronic pancreatitis cholangiocarcinoma healthy control anticipated participants: 34
Venous sampling
venous sampling of 12ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venous sampling
venous sampling of 12ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* pancreatic cancer patients
* pancreatic lesions other than PAAD
* chronic pancreatitis
* cholangiocarcinoma
Exclusion Criteria
* treated with chemo/radio/surgery previously
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin Cheng
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital, Tongji Medical College, HUST
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Bin Cheng, Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-sR2020
Identifier Type: -
Identifier Source: org_study_id